Aprea Therapeutics, Inc. Net Fee Amt
Aprea Therapeutics, Inc. (APRE) had Net Fee Amt of $9.48 thousand as of 2026-04-21, per its S-3 filed 2026-04-22.
Financial Statements › Notes
ffd:NetFeeAmt · last filed 2026-04-22
- 2026-04-21: Net Fee Amt $9.48K.
| Period end | Net Fee Amt |
|---|---|
| 2026-04-21 | $9.48K S-3 · filed 2026-04-22 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Medicus Pharma Ltd. (MDCX) | $0.010B | ||
| Azitra, Inc. (AZTR) | United States | $0.010B | -0.81 |
| FibroBiologics, Inc. (FBLG) | United States | $0.009B | -0.27 |
| Alzamend Neuro, Inc. (ALZN) | United States | $0.009B | |
| Theriva Biologics, Inc. (TOVX) | United States | $0.011B | |
| Traws Pharma, Inc. (TRAW) | United States | $0.009B | -0.58 |
| KALA BIO, Inc. (KALA) | United States | $0.011B | -3.33 |
| MetaVia Inc. (MTVA) | United States | $0.011B | -0.65 |
| Moleculin Biotech, Inc. (MBRX) | United States | $0.011B | |
| Imunon, Inc. (IMNN) | United States | $0.008B | -0.56 |